Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in early type 2 diabetes
NCT05433584Phase 4Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 4 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Aug 2022; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05433584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433584.